Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

571
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
571
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

14
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
14
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

226
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
226
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

215
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
215

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin or clopidogrel in chronic coronary syndromes: the saga continues.

European heart journal·2026
Same author

Diuretic dose and right atrial function interplay in patients with tricuspid regurgitation.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026
Same author

Weekly Journal Scan: Not all direct oral anticoagulants are created equal.

European heart journal·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026
Same author

Antidotes for Anticoagulation Reversal.

The New England journal of medicine·2026

Related Experiment Video

Updated: Jul 29, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

650

Precision antiplatelet therapy.

Bianca Rocca1, Carlo Patrono1

  • 1Section of Pharmacology, Catholic University School of Medicine and Fondazione Policlinico Universitario Agostino Gemelli and Istituto di Ricerca e Cura a Carattere Scientifico, Rome, Italy.

Research and Practice in Thrombosis and Haemostasis
|May 22, 2023
PubMed
Summary

Precision pharmacology personalizes antiplatelet therapy by using biomarkers to tailor drug regimens. This approach optimizes the benefit-risk balance for individual patients, improving drug efficacy and safety.

Keywords:
arterial occlusive diseasesaspirinplatelet aggregation inhibitorsprecision medicinepurinergic P2Y receptor antagonists

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.1K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.7K

Related Experiment Videos

Last Updated: Jul 29, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

650
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.1K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis and Haemostasis

Background:

  • Variability in drug response can lead to serious side effects, particularly with antiplatelet drugs and direct oral anticoagulants.
  • Precision pharmacology aims to optimize the benefit-risk balance of drug regimens for individual patients.

Purpose of the Study:

  • To critically analyze tools for precision dosing of antiplatelet therapy.
  • To exemplify how precision dosing can enhance the efficacy and safety of aspirin and P2Y12 receptor blockers.

Main Methods:

  • Utilizing genetic, biochemical, and pharmacological biomarkers to identify sources of drug response variability.
  • Employing in silico pharmacokinetic/pharmacodynamic models and simulations with real-world biomarker data.
  • Reviewing new data on precision dosing presented at the 2022 ISTH Congress.

Main Results:

  • Biomarkers are crucial for identifying target populations, characterizing response variability, and guiding precision treatments.
  • In silico models, informed by biomarkers, aid in guiding precision pharmacology.
  • Precision dosing can significantly improve the efficacy and safety of antiplatelet agents.

Conclusions:

  • Precision pharmacology, guided by biomarkers and in silico models, offers a powerful approach to personalize antiplatelet therapy.
  • Tailoring antiplatelet drug regimens based on individual patient characteristics maximizes therapeutic benefits while minimizing risks.
  • The 2022 ISTH Congress highlighted advancements in personalizing antiplatelet therapy through precision dosing strategies.